Drug Profile
Research programme: renal and lung cancer gene therapy - Candel Therapeutics
Alternative Names: ADV 005; Adv-005; TKI therapyLatest Information Update: 14 Nov 2021
Price :
$50
*
At a glance
- Originator Advantagene
- Class
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Lung cancer; Renal cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Lung-cancer in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Renal-cancer in USA
- 01 Sep 2006 Preclinical trials in Lung cancer in USA (unspecified route)